Open AccessEffectiveness of Azithromycin As Therapy Covid-19
Author(s) -
Nurul Hidayah,
Denova Haryavany
Publication year - 2022
Publication title -
journal pharmasci (journal of pharmacy and science)/journal pharmasci (journal of pharmacy and science)
Language(s) - English
Resource type - Journals
eISSN - 2549-3558
pISSN - 2527-6328
DOI - 10.53342/pharmasci.v7i1.276
Subject(s) - azithromycin , hydroxychloroquine , medicine , covid-19 , pandemic , disease , combination therapy , infectious disease (medical specialty) , antibiotics , biology , microbiology and biotechnology
Corona virus infection 2019 (COVID-19) is an infectious disease caused by SARS-CoV-2. Covid-19 has been declared a pandemic by the WHO, where the scale of the spread of the disease occurs globally. Azithromycin alone and its combination with hydroxychloroquine has been proposed as a treatment that can improve the prognosis of COVID-19. The purpose of this review is to determine the use of doses and how long azithromycin is active in COVID-19 patients. This research method uses a literature review of articles through internet searches by accessing the database from the google scholar site, pubmed. The object of this research is a scientific article published in the period 2017-2021 and relates to the effectiveness of azithromycin as a therapy to treat Covid-19 infection in humans. The results of the literature study show that Azithromycin has the potential as a therapy in COVID-19 patients, either alone or in combination. The average duration of azithromycin administration was 5 days, of which 500 mg was the loading dose followed by 250 mg for the next 4 days. The effectiveness of Azithromycin either alone or in combination with hydroxychloroquine (HCQ) showed effectiveness in reducing viral load where the decline began on day 6 and complete recovery of the patient was achieved on day 10 to day 12. The conclusion of this study is that Azithromycin has the potential as a therapy in COVID-19 patients, either alone or in combination.